Future use of mitocans against tumour-initiating cells?

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68378050%3A_____%2F09%3A00325050" target="_blank" >RIV/68378050:_____/09:00325050 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/86652036:_____/09:00325050

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Future use of mitocans against tumour-initiating cells?

Popis výsledku v původním jazyce

Tumour heterogeneity has several important consequences including making their classification by morphological and genetic analysis more difficult because of the diversity of cells, failing to eliminate one of the cell subtypes and differing abilities ofthe cell subtypes for dissemination and metastasis. Recently, a rare subpopulation of cells within tumours has been described with the ability to initiate and sustain tumour growth, to resist traditional therapies and to allow for secondary tumour dissemination. These cells are termed tumour-initiating cells (TICs). Understanding tumour heterogeneity will be critical for advancing treatments for cancer that target TIC subpopulations of cells in a tumour able to resist traditional treatments and eliminate them before metastatic disease occurs. Therefore, knowledge of the molecular mechanism(s) of resistance of TICs to treatment and overcoming it will be essential in order to develop effective drug strategies for cancer therapy.

Název v anglickém jazyce

Future use of mitocans against tumour-initiating cells?

Popis výsledku anglicky

Tumour heterogeneity has several important consequences including making their classification by morphological and genetic analysis more difficult because of the diversity of cells, failing to eliminate one of the cell subtypes and differing abilities ofthe cell subtypes for dissemination and metastasis. Recently, a rare subpopulation of cells within tumours has been described with the ability to initiate and sustain tumour growth, to resist traditional therapies and to allow for secondary tumour dissemination. These cells are termed tumour-initiating cells (TICs). Understanding tumour heterogeneity will be critical for advancing treatments for cancer that target TIC subpopulations of cells in a tumour able to resist traditional treatments and eliminate them before metastatic disease occurs. Therefore, knowledge of the molecular mechanism(s) of resistance of TICs to treatment and overcoming it will be essential in order to develop effective drug strategies for cancer therapy.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

EB - Genetika a molekulární biologie

OECD FORD obor

—

Projekt

—

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2009

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Molecular Nutrition & Food Research

ISSN

1613-4125

e-ISSN

—

Svazek periodika

53

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

7

Strana od-do

—

Kód UT WoS článku

000262869400013

EID výsledku v databázi Scopus

—